Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The phosphinothricin acetyltransferase (PAT) gene, derived from the soil bacteria *Streptomyces hygroscopicus* (bar) or *Streptomyces viridochromogenes* (pat), encodes an enzyme (PAT) that detoxifies the herbicide glufosinate (phosphinothricin) by acetylation. Transgenic crops expressing this gene are rendered tolerant to glufosinate by converting the herbicide into N-acetyl-glufosinate, a non-toxic compound that can no longer inhibit the endogenous plant enzyme glutamine synthetase—thus ensuring crop survival after herbicide application. This gene is used as a selectable marker and trait gene in various genetically modified crops such as maize, cotton, and canola. "Glufosinate tolerance gene" should be replaced with the precise name of the conferred trait gene, "phosphinothricin acetyltransferase." Key extra details: - Mechanism: Glufosinate acts by inhibiting plant glutamine synthetase, causing ammonia toxicity and death. The PAT enzyme catalyzes acetylation of glufosinate, rendering it unable to bind glutamine synthetase, thereby protecting transformed plants. - Commercial use: Present in LibertyLink® and other glufosinate-tolerant crops. - Transgene marker: Used for selection during the generation of GM plants. Glufosinate tolerance can rarely arise via mutations in plant glutamine synthetase genes, but in agricultural biotechnology, the term almost always refers to the bacterial PAT/BAR transgene.
Acetylation (detoxification) of glufosinate to non-toxic N-acetyl-glufosinate
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphinothricin acetyltransferase (PAT (sometimes "BAR" when using the bar gene variant)).